Active, not recruitingPhase 2NCT04417062

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Studying Bone sarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Dana-Farber Cancer Institute
Principal Investigator
Katherine Janeway, MD
Dana-Farber Cancer Institute
Intervention
Olaparib(drug)
Enrollment
63 target
Eligibility
12-40 years · All sexes
Timeline
2020 – 2026

Study locations (4)

Collaborators

Osteosarcoma Institute · AstraZeneca

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04417062 on ClinicalTrials.gov

Other trials for Bone sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Bone sarcoma →

← Back to all trials